Medtronic Wins Approval for Device to Resynchronize Heart
This article is for subscribers only.
Medtronic Inc. won U.S. regulatory approval for its Viva device used to resynchronize the beating of the heart and reduce hospitalizations for heart failure.
The permanently implanted device uses an algorithm to coordinate the heart’s 100,000 contractions each day, adjusting to varying demands of the body as the user goes through regular daily activities. The sophisticated system removes the need for doctors to recalibrate the device at regular visits and improves the battery life by 25 percent compared with older models, Minneapolis-based Medtronic said today in a statement.